济民健康公告，持股24.37%的控股股东双鸽集团因自身资金需求，计划在2025年9月29日至2025年12月 26日，通过集中竞价及大宗交易方式合计减持不超过1575.27万股，即不超过公司总股本的3%，其中集 中竞价不超过525.09万股，大宗交易不超过1050.18万股。 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-044 济民健康管理股份有限公司 截至本减持计划公告之日，双鸽集团有限公司(以下简称"双鸽集团")持有 济民健康管理股份有限公司（以下简称"公司"）股份 127,983,520 股，占公司 总股本的 24.37%，上述股份全部来源于公司首次公开发行前已持有的股份及上 市后资本公积转增股本取得的股份。 减持计划的主要内容 双鸽集团因自身资金需求，计划以集中竞价交易方式和大宗交易方式减持公 司合计不超过 15,752,718 股股份，即不超过公司总股本的 3%（若计划减持期间 有派息、送股、资本公积金转增股本、配股等除权除息事项，拟减持股份数量和 减持价格将相应进行调整），本次减持将在本减持计划公告之日起十五个交易日 后的 3 个月内进行,其中通过集中竞价交易方式减持股份不超过公司总股本的 1%， 通过大宗交易方式减持股份不超过公司总股本的 2%。 1 股东名称 双鸽集团 股东身份 控股股东、实控人及一致行动人 √是 □否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他：不适用 一、减持主体的基本情况 本公司董事会、全 ...

人民财讯9月4日电，济民健康（603222）9月4日晚间公告，公司控股股东、实控人之一致行动人双鸽集 团有限公司计划15个交易日后的3个月内，以集中竞价和大宗交易方式，减持公司股份合计不超过 1575.27万股，即不超过公司总股本的3%。 ...

（文章来源：每日经济新闻） 每经AI快讯，9月4日，济民健康(603222.SH)公告称，公司股东双鸽集团因自身资金需求，计划以集中 竞价交易和大宗交易方式减持公司股份合计不超过1575.27万股，即不超过公司总股本的3%。减持将在 公告之日起十五个交易日后的3个月内进行，其中通过集中竞价交易方式减持不超过1%，通过大宗交易 方式减持不超过2%。减持价格将根据市场情况和公司股价进行调整。双鸽集团承诺将严格遵守相关法 律法规和监管要求，及时履行信息披露义务。 ...

济民健康（603222）(603222.SH)公告，公司股东双鸽集团计划以集中竞价交易方式和大宗交易方式减 持公司合计不超过1575.27万股股份，即不超过公司总股本的3%。 ...

智通财经APP讯，济民健康(603222.SH)公告，公司股东双鸽集团计划以集中竞价交易方式和大宗交易 方式减持公司合计不超过1575.27万股股份，即不超过公司总股本的3%。 ...

Group 1 - The medical device sector experienced a slight adjustment on September 4, outperforming the broader market, with the medical device ETF (562600) declining by 1.58% while stocks like Jimin Health and Haooubo rose by 10.03% and 6.45% respectively [1] - The medical device ETF (562600) attracted a total of 34.1 million yuan in capital over the past 10 days, indicating strong investor interest [1] - The Shaanxi Provincial Drug Administration reported achievements in high-quality drug regulation during the 14th Five-Year Plan, including 100% coverage of clinical trial supervision and inspections of 4,839 medical device production processes [1] Group 2 - Guotai Junan Securities noted that the medical device sector's revenue for Q2 2025 decreased by 4.77% year-on-year, attributed to extended revenue recognition cycles and inventory clearance needs among companies [2] - The medical device sector has seen a 23.3% increase year-to-date as of August 29, 2025, ranking 4th among sub-sectors in the pharmaceutical and biological industry, with domestic innovation support policies significantly impacting industry valuations [2] - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device industry, tracking the CSI All-Share Medical Device Index, which has a high concentration of 89.34% in the medical device sector [2]

Group 1: Company Developments - Anzheng Fashion focuses on mid-to-high-end brand fashion, achieving a turnaround in net profit year-on-year in the first half of the year [2] - Zhengye Technology's subsidiary has mastered the "silver-free process" for heterojunction battery technology [2] - Meibang Clothing, a leading domestic leisure apparel brand, is set to enhance its production capacity for foldable screens significantly by 2025 [3] Group 2: Industry Trends - The State Council emphasizes the acceleration of service consumption and new consumption growth points [2] - The demand for data centers and energy storage is expected to grow rapidly [4] - The National Development and Reform Commission is promoting the development of the biopharmaceutical industry among central enterprises [4] Group 3: Market Movements - Companies like Tongrun Equipment and China Ruilin are experiencing stock price increases, with Tongrun Equipment's stock rising for two consecutive days [4] - The international gold price has reached a historical high, benefiting companies like Eurasia Group, which collaborates with well-known gold brands [4] - The stock price of Pop Mart has reached a new historical high, indicating strong market interest in IP economy [5]

Core Viewpoint - Jimin Health (SH603222) reached its daily limit with a price of 12.54 yuan, marking a 10.03% increase and a total market capitalization of 6.049 billion yuan, driven by share buybacks, employee incentives, and strategic industry transformation [1] Group 1: Share Buyback and Employee Incentives - The company plans to repurchase 100 to 200 million yuan worth of shares, indicating confidence in its development and aiming to enhance employee motivation by tying core talent to the company's performance [1] - The repurchase is intended for employee incentives, which is expected to improve employee engagement and retention [1] Group 2: Industry Transformation Strategy - Jimin Health is participating in a venture development fund, showcasing its strategic intent for industry transformation and upgrade, which has positively influenced market expectations [1] - The company's main business segments include medical services, medical devices, and large-volume infusion, with the medical device sector currently attracting market attention [1] Group 3: Market Activity and Stock Performance - The stock has frequently appeared on the "Dragon and Tiger List," indicating active market trading, with significant participation from speculative funds [1] - On September 2, the trading volume reached 1.331 billion yuan, reflecting strong interest in the medical device sector and contributing to the stock's price increase [1] - The buying and selling data from the Dragon and Tiger List shows a net inflow of funds, with total purchases of 193 million yuan and total sales of 164 million yuan on September 2, which helped drive the stock to its limit [1]

8月21日公司发布的半年报数据显示，上半年公司共实现营业总收入3.66亿元，同比下降21.30%，实现 净利润-0.53亿元，同比下降307.10%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.09.03 | -8.16 | 18.86 | -10062.32 | | 2025.09.02 | -10.02 | 20.68 | -18093.89 | | 2025.09.01 | 9.98 | 20.01 | 10684.43 | | 2025.08.29 | 4.35 | 22.32 | 1215.91 | | 2025.08.28 | 9.96 | 24.19 | 12589.52 | | 2025.08.27 | 9.97 | 22.20 | 11804.67 | | 2025.08.26 | -7.68 | 19.33 | -17817.37 | | 2025.08.25 | -3.61 | 19.08 | -2742.82 | | 2025.08.22 | -10.00 ...